Wednesday, the New England Journal of Medicine published full study data from the Phase 2/3 trial of Pfizer Inc’s (NYSE:PFE) Paxlovid (Nirmatrelvir in combination with ritonavir). They shared initial data in 2022. The study enrolled adult vaccinated patients with COVID-19 who had at least one risk factor for severe disease and patients without risk factors who had never been vaccinated or had not received a vaccine in the past year. Participants were given either Paxlovid or a placebo. Related: Pfizer’s COVID-19 Treatment Paxlovid Will No Longer Be Available For Emergency Use After This Date, FDA Revises Label. The publication notes that the efficacy of this treatment in patients who are ...